CYCLERION THERAPEUTICS, INC. Earnings Per Share (Basic)
CYCLERION THERAPEUTICS, INC. (CYCN) reported Earnings Per Share (Basic) of -$0.41 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-04
- CYCLERION THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.41.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.76.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.21, a 200.56% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.30.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$2.25.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$20.28.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic for fiscal 2021 was -$1.32.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.41 10-Q · filed 2026-08-04 | -$1.17 10-Q · filed 2026-08-04 | -$1.40 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.73 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2026-03-31 | -$0.76 S-4/A · filed 2026-07-22 | -$0.99 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.32 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.47 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2025-12-31 | -$0.21 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.11 S-4/A · filed 2026-07-22 | ||||
| 2025-09-30 | -$0.30 10-Q · filed 2025-11-12 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$0.92 10-Q · filed 2025-11-12 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2025-06-30 | -$0.11 10-Q · filed 2026-08-04 | -$0.62 10-Q · filed 2026-08-04 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2025-03-31 | -$0.56 S-4/A · filed 2026-07-22 | -$0.35 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2024-12-31 | $0.21 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$0.08 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$1.21 S-4/A · filed 2026-07-22 | ||||
| 2024-09-30 | -$0.29 10-Q · filed 2025-11-12 | -$0.81 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.43 10-Q · filed 2025-11-12 | -$2.12 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||||
| 2024-06-30 | -$0.53 10-Q · filed 2025-08-05 | -$1.14 10-Q · filed 2025-08-05 | -$1.83 derived: net income ÷ weighted average shares · filed 2025-11-12 | $1.22 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||||
| 2024-03-31 | -$0.62 10-Q · filed 2025-05-06 | -$1.31 derived: net income ÷ weighted average shares · filed 2025-11-12 | $1.76 derived: net income ÷ weighted average shares · filed 2025-11-12 | $0.06 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||||
| 2023-12-31 | -$0.69 derived: net income ÷ weighted average shares · filed 2025-11-12 | $2.40 derived: net income ÷ weighted average shares · filed 2025-11-12 | $0.71 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$2.25 10-K/A · filed 2025-11-12 | ||||
| 2023-09-30 | $3.10 10-Q · filed 2024-11-14 | $3.11 10-Q · filed 2023-11-13 | $1.44 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$1.55 10-Q · filed 2024-11-14 | -$4.76 derived: net income ÷ weighted average shares · filed 2024-11-14 | |||
| 2023-06-30 | -$1.83 10-Q · filed 2024-08-07 | -$5.00 10-Q · filed 2024-08-07 | -$8.30 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$13.10 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2023-03-31 | -$3.20 10-Q · filed 2024-05-07 | -$0.16 10-Q · filed 2023-05-12 | -$6.52 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$11.34 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$17.50 derived: net income ÷ weighted average shares · filed 2024-11-14 | |||
| 2022-12-31 | -$3.32 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$8.15 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$14.31 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$20.28 10-K · filed 2024-03-05 | -$1.01 10-K · filed 2023-03-22 | |||
| 2022-09-30 | -$4.83 10-Q · filed 2023-11-13 | -$0.24 10-Q · filed 2022-11-03 | -$10.99 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$16.96 10-Q · filed 2023-11-13 | -$0.85 10-Q · filed 2022-11-03 | -$3.99 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||
| 2022-06-30 | -$6.16 10-Q · filed 2023-07-28 | -$0.31 10-Q · filed 2022-08-09 | -$12.14 10-Q · filed 2023-07-28 | -$0.61 10-Q · filed 2022-08-09 | -$2.44 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$2.18 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||
| 2022-03-31 | -$0.30 10-Q · filed 2023-05-12 | -$1.09 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.21 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.67 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||||
| 2021-12-31 | -$0.25 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$0.51 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$0.94 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$1.32 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | -$0.26 10-Q · filed 2022-11-03 | -$0.70 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.08 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | -$0.45 10-Q · filed 2022-08-09 | -$0.85 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |